GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer
8mo agoen
From the article
ADC complements GSK’s diverse pipeline in prostate cancer anchored by GSK’227, a B7H3-targeted ADC.
Continue reading on GSKYou might also wanna read

How Insurers Use Copay Accumulator Programs to Undermine Drug Assistance for Patients
This article investigates how health insurers use "copay accumulator" programs to prevent drug manufacturer copay assistance coupons from co

Vets issue urgent warning to pet owners as flesh-eating screwworm spreads through Texas and New Mexico
FORTUNE·7h ago

Australia news live: Telstra warns of ‘secondary issue’ after yesterday’s network outage; trains in regional Victoria cancelled again
The Guardian·8h ago
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
pharmaphorum·9h ago
UPMC returns to profitability with $380M profit after two years of losses
UPMC returned to profitability in fiscal year 2024-2025 with a profit of over $380 million, reversing two years of historically large losses
How Front-Desk Friction Drives Patient Churn Despite High Clinical Satisfaction
A primary-care patient rated her physician highly but left the practice due to poor front-desk experiences — specifically, long phone wait t

Comments
Sign in to join the conversation.
No comments yet. Be the first.